Generic drug manufacturer TWi Pharmaceuticals (and its predecessor Anchen Pharmaceuticals) sought to market a generic version of Cephalon’s Amrix®—a medication used to help control muscle spasms associated with acute, painful musculoskeletal conditions. Cephalon filed suit alleging that TWi’s generic version infringed several patents.
We obtained a ruling that TWi did not infringe any patents. After the Court’s order in favor of TWi, our team filed a motion to deem the case exceptional and for recovery of attorneys’ fees. The Court granted our motion and awarded TWi its attorneys’ fees.